Prepare to overcome your supply issues in 2022 by developing a high-performing supply chain for the cGMP chemicals critical to your biologic manufacturing. Download now!
In response to being told that they would be fired if they did not get vaccinated against COVID-19, four Bristol Myers Squibb employees have filed a lawsuit against the company claiming the drugmaker wrongfully denied their requests for religious exemptions.
The PerkinElmer Lead Discovery Premium Biotech Bundle empowers you to find and understand trends and outliers in your data to ensure successful candidate selection. On the AWS Cloud, affordable, easy to deploy. Learn more.
CVS Health is tapping into Microsoft's technologies, including cloud computing, to accelerate its "digital-first" strategy. The pharmacy retail company announced Thursday a new strategic alliance with the tech giant focused on developing innovative solutions to provide more personalized care to consumers.
The SEC charged former Immunomedics Chief Financial Officer Usama Malik with insider trading during his time at the biopharma, now owned by Gilead. As a result, Malik was fired as CEO and director of his current employer, Fore Biotherapeutics, where he lasted less than a year.
Nearly two years after the Trump administration tasked private health insurers with reimbursing the total costs of point-of-care COVID tests and health services, Biden will expand that requirement to include at-home tests, too.
Novartis is bracing for several losses of market exclusivity in the next five years, most notably for the company’s second-best-selling drug, Entresto. To hear CEO Vas Narasimhan tell it, the Swiss pharma is advancing more than enough programs to cushion the generics impact and drive growth in the long run, with or without acquisitions.
Google is introducing new search features to make finding health information more accessible, addressing questions like whether a provider accepts Medicare or what languages that provider speaks, according to a Thursday blog post.
Novartis is betting $150 million on a rival to Parkinson’s disease drugs in development at companies including Roche and AstraZeneca. The deal sees Novartis commit to pay UCB up to around $1.5 billion in milestones for the chance to co-develop a midphase Parkinson’s prospect.
Australian biotech giant CSL is negotiating with Vifor Pharma to acquire the Swiss company for A$10 billion ($7.1 billion), says the Australian Financial Review. The acquisition would become the largest ever for CSL.
Venclose’s solution uses a radiofrequency ablation catheter threaded into the compromised vein to deliver heat and shrink the vessel. Once complete, the blood will naturally reroute its flow to nearby healthy veins.
Acepodia is doubling down on its cancer cell therapy development with a $109 million series C round. The funding comes after a $47 million B round in March and multiple C-suite hires since then. Acepodia's lead asset is in a phase 1 trial in HER2-positive tumors.
Apparently not content to work toward improving cancer care from just one angle, Johnson & Johnson’s Janssen R&D unit and molecular data gatherer Tempus have expanded their partnership.
A newly published analysis of hospitals' published imaging prices found limited compliance with CMS' price transparency rule as well as a stark range of hundreds or thousands of dollars between the prices they're charging Medicare and commercial payers.
Real Chemistry has been on a growth tear over the last two years, gobbling up smaller companies and adding hundreds of new hires. It also more than doubled its revenues, which are expected to approach the half-billion-dollar mark this year. Now it's getting a new top executive.
